Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Obesity

    Lewes, DE

    Search
    Obesity
    Lewes, DE
    Show Map
    Map View
    Lewes, DE
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      143 Obesity Trials near Lewes, DE

      Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Mobile Integrated Care for Childhood Obesity

      Millsboro, Delaware
      The goal of this clinical trial is to evaluate a new way of providing healthcare to children with an unhealthy weight. Families who participate will be assigned by chance to one of two groups. One group will see their child's primary care provider to talk about healthy lifestyles for 6 months. The other group will be in our Healthy Lifestyle program for 6 months. This will include: * Check-ins with lifestyle specialists and community health workers, * A mobile app to help support a healthy lifestyle, and * Access to community programs and activities. The main questions the study aims to answer are: * Do children in the Healthy Lifestyle program have better weight outcomes? * Do more families in the Healthy Lifestyle program stay in the study? * Does the Healthy Lifestyle program work better for families from certain communities?
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:4+

      Key Eligibility Criteria

      Disqualifiers:Genetic Syndrome, Endocrine Disorder, Others
      Must Not Be Taking:Weight-impacting Medications

      59 Participants Needed

      BI 456906 for Diabetes and Obesity

      Atlantic City, New Jersey
      This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Gastric Issues, Pancreatitis, Thyroid Cancer, Others
      Must Be Taking:Diet, Exercise

      755 Participants Needed

      Inclisiran for Cardiovascular Disease Prevention

      Elmer, New Jersey
      This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 79

      Key Eligibility Criteria

      Disqualifiers:ASCVD, Revascularization, Liver Disease, Others
      Must Be Taking:Lipid Lowering

      14082 Participants Needed

      Maridebart Cafraglutide for Cardiovascular Disease

      Wilmington, Delaware
      The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45 - 99

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Type 1 DM, Others
      Must Not Be Taking:GLP-1 RAs, GIP Agonists

      12800 Participants Needed

      Tirzepatide for Adolescent Obesity

      Wilmington, Delaware
      The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Type 2 Diabetes, Pancreatitis, Medullary Thyroid Carcinoma, Others

      300 Participants Needed

      Tirzepatide + Mibavademab for Obesity

      Berlin, New Jersey
      The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Thyroid Carcinoma, Hepatitis, Others

      360 Participants Needed

      GV101 for Obesity

      Berlin, New Jersey
      The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Drug Misuse, Others
      Must Not Be Taking:Corticosteroids, Antidepressants, Antipsychotics, Others

      130 Participants Needed

      Trevogrumab + Garetosmab + Semaglutide for Obesity

      Berlin, New Jersey
      This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Bariatric Surgery, Hypertension, Others

      1005 Participants Needed

      Produce Prescription for Obesity

      Wilmington, Delaware
      The goal of this research study is to learn if an 8-week produce prescription program (in partnership with a local urban farm) can increase fruit and vegetable consumption in overweight teens and improve their blood pressure and weight. The main questions are: * Is a produce prescription program in overweight teens feasible? * Will a produce prescription with educational videos increase weekly fruit and vegetable intake? * Will a produce prescription with educational videos improve blood pressure and weight for height? Researchers will compare the teens' fruit and vegetable intake, blood pressure and weight for height before and after the produce prescription. Researchers will also see how feasible it is by measuring the number of produce prescriptions are picked up by the families and how many educational videos are viewed. Participants will: * complete questionnaires related to their diet and nutrition * measure their blood pressure and weight at the beginning and end of the study * obtain weekly produce prescriptions
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Neurocognitive Delays, G-tube/J-tube, Food Allergies

      50 Participants Needed

      Tirzepatide for Obesity

      Berlin, New Jersey
      This trial is testing tirzepatide, a medication that helps control blood sugar and reduce appetite, to see if it can lower health problems and death rates in adults who are very overweight. Tirzepatide was developed by Eli Lilly to improve blood sugar control in adults with type 2 diabetes.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Recent MI, Pancreatitis, Others

      15374 Participants Needed

      Food Program for Pregnancy Complications

      Newark, Delaware
      The purpose of this study is to conduct a pilot randomized controlled trial of a food is medicine community health worker intervention called the Women's Health Delaware Food Farmacy compared to the usual standard of care among pregnant ChristianaCare patients at risk for adverse clinical outcomes. The pilot study has three specific aims: Aim 1: To assess the feasibility of the Women's Health Delaware Food Farmacy and refine the program as needed Aim 2: To determine the prevalence of and change in social needs Aim 3: To evaluate the effectiveness of the Women's Health Delaware Food Farmacy on maternal and child health, healthcare utilization, and clinical event outcomes as well as patient-reported outcomes compared to the usual standard of care
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Multiple Pregnancy, Others

      250 Participants Needed

      ALN-4324 for Obesity

      Berlin, New Jersey
      The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis C, Hepatitis B, Others

      144 Participants Needed

      Maridebart Cafraglutide for Obesity

      Annapolis, Maryland
      The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Pancreatitis, Severe Psychiatric Disorder, Others

      1105 Participants Needed

      MET097 for Obesity

      Marlton, New Jersey
      This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Pancreatitis, MDD, Others
      Must Be Taking:Blood Pressure, Lipid-lowering

      250 Participants Needed

      HealthyWE for Obesity

      Camden, New Jersey
      The goal of this project was to reduce and manage obesity and increase self-efficacy for keeping a healthy weight and improve pain, quality of life, and mental health symptoms among 60 adults aged 19 and older in Camden City, New Jersey. The City of Camden has an adult obesity rate of 44.1%. Obesity and aging are significant contributing factors to increased utilizations of healthcare services. Obesity is a major risk factor for non-communicable illnesses such as cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, pain, and mental health. Physical activity is effective in reducing and managing obesity. However, personal barriers (e.g., lack of time for physical activity, physical capability to perform physical activities, competing demands), built environment (e.g., safe spaces for physical activities), climate changes (e.g., heat waves and extreme weather which prevent outdoor physical activities), and systematic barriers (e.g., intervention availability) hamper obesity prevention and management in older adult population. To help older adults keep a healthy weight, our team has adapted and delivered the effective person-centered integrative interventions: HealthyWE: Keeping a Healthy Weight program to older adults in Camden New Jersey. Completion of the project will build a strong community capacity in Camden to sustain a community effort to reduce obesity and pain.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:19+

      Key Eligibility Criteria

      Disqualifiers:Disability, Dementia, Alzheimer's, Others

      80 Participants Needed

      Retatrutide for Obesity

      Upland, Pennsylvania
      The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45+

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others

      10000 Participants Needed

      Retatrutide for Obesity

      Baltimore, Maryland
      The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Thyroid Cancer, Pancreatitis, Others
      Must Not Be Taking:Weight Loss Drugs

      250 Participants Needed

      Maridebart Cafraglutide for Heart Failure

      Bowie, Maryland
      This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The study is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Psychiatric, Others
      Must Be Taking:Standard HF Therapies

      5056 Participants Needed

      Tirzepatide for Type 1 Diabetes and Obesity

      West Chester, Pennsylvania
      The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Hypoglycemia, Pancreatitis, Others
      Must Be Taking:Insulin

      905 Participants Needed

      CagriSema vs. Tirzepatide for Weight Loss in Obesity

      Philadelphia, Pennsylvania
      This trial tests if a new combination of two drugs, given regularly, helps people lose weight better than another treatment. It targets individuals needing to lower their body weight by helping them feel less hungry and manage their weight. Two different drugs are being investigated as options for weight management.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetes

      809 Participants Needed

      Why Other Patients Applied

      "I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."

      JP
      Obesity PatientAge: 44

      "I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."

      MW
      Parent of PatientAge: 46

      "I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."

      KI
      Obesity PatientAge: 69

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."

      DK
      Obesity PatientAge: 56
      Match to a Obesity Trial

      Setmelanotide for Hypothalamic Obesity

      Philadelphia, Pennsylvania
      This trial tests if Setmelanotide, an injection, can help reduce weight and hunger in patients aged 4 and older with acquired Hypothalamic Obesity. The medication works by targeting brain pathways that control hunger and energy use. Setmelanotide has been approved for treating obesity in rare genetic conditions and is being developed for other obesity-related disorders.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4+

      Key Eligibility Criteria

      Disqualifiers:Prader-Willi, ROHHADNET, Severe Psychiatric, Others

      120 Participants Needed

      Semaglutide for Childhood Obesity

      Baltimore, Maryland
      This trial will test if semaglutide helps children and teenagers lose weight. Participants will receive regular injections of semaglutide and will also get advice on healthy eating and physical activity. The study aims to see if semaglutide can help this age group manage their weight better.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 18

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Endocrine Obesity, Others
      Must Not Be Taking:Obesity Medications

      210 Participants Needed

      CagriSema for Obesity

      Philadelphia, Pennsylvania
      This trial tests how well different treatments help people with excess body weight lose weight. Participants will receive one of four treatments through regular injections. The study will last over a year, followed by a period to observe long-term effects.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Others

      3400 Participants Needed

      Setmelanotide for Obesity

      Philadelphia, Pennsylvania
      The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-study 035b) * SRC1 (Sub-study 035c) * SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 65

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Disorders, Suicidal Ideation, Pulmonary, Cardiac, Endocrine, Others

      400 Participants Needed

      Liraglutide for Childhood Obesity

      Baltimore, Maryland
      The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 12

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Secondary Obesity, Others
      Must Not Be Taking:Obesity Medications

      78 Participants Needed

      Semaglutide for Obesity

      Baltimore, Maryland
      The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:12 - 15

      Key Eligibility Criteria

      Disqualifiers:Prepubertal, Obesity Surgery, Diabetes, Others
      Must Be Taking:Semaglutide

      500 Participants Needed

      Tirzepatide for Binge Eating Disorder

      Baltimore, Maryland
      The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Bulimia, Severe Psychiatric Disorders, Others
      Must Not Be Taking:MAOIs, Psychostimulants, Weight-loss Drugs

      105 Participants Needed

      Digital Intervention for Binge Eating

      Philadelphia, Pennsylvania
      The proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants. Participants will be recruited for this single group pilot trial using online advertising to attend a virtual screening session. Screened participants willing and eligible to participate, will receive informed consent and formally start ChangeBite. Participants will be instructed to engage with ChangeBite and attend follow up assessments on scheduled video calls. Feasibility and acceptability of implementation will be assessed by collecting data on recruitment, retention, usability and satisfaction. The research team will also collect assessment data from participants on feasibility, and usability. In addition to self report scales, semi-structured interviews will be completed with a trained research team member via video call and will be partially recorded. Assessments will be done at baseline, 12 weeks, and 24 weeks. Participants' app use frequency and duration will be tracked using software analytics. Participants' body weight will be captured weekly using a timestamped picture of their weight as it appears on their scale and Body Mass Index will be calculated with these data points.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Eating Disorder Treatment, Weight Loss Treatment, Severe Psychopathology, Pregnancy, Others
      Must Not Be Taking:Antipsychotics

      30 Participants Needed

      Phentermine/Topiramate for Hypothalamic Obesity

      Philadelphia, Pennsylvania
      Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness. Preliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 6-28-year-old individuals with HO.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:6 - 28

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Conditions, Diabetes, Liver Disease, Others
      Must Be Taking:Pituitary Replacements, Appetite-modulating

      24 Participants Needed

      Metformin for Asthma

      Baltimore, Maryland
      This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiovascular Disease, Diabetes, Others
      Must Not Be Taking:GLP-1, Metformin

      100 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Obesity clinical trials in Lewes, DE pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Obesity clinical trials in Lewes, DE work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Lewes, DE 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Lewes, DE for Obesity is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Lewes, DE several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Obesity medical study in Lewes, DE?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Obesity clinical trials in Lewes, DE?

      Most recently, we added Exercise Intervention for Obesity and Sarcopenia, Cagrilintide + CagriSema for Childhood Obesity and Gamification for Hospital Mobility Improvement to the Power online platform.

      What is the new treatment for obesity?

      The “new” treatments are weekly injections of GLP-1–based drugs such as semaglutide (Wegovy) and the dual GIP/GLP-1 drug tirzepatide (Zepbound), which curb appetite and slow stomach emptying; in large trials they helped adults lose roughly 15-22 % of their starting weight over 12–18 months when combined with diet and exercise. They are prescription-only, must be used long-term to keep the weight off, and while most side-effects are mild stomach upset, they can be expensive and require close medical follow-up—so you and your clinician should weigh these pros and cons against other options like older pills, bariatric surgery, and structured lifestyle programs.

      How much do I get paid for a clinical trial?

      There is no single rate, but in the U.S. healthy-volunteer Phase I studies usually pay about $75–$150 for a short outpatient visit or $300–$500 per overnight, adding up to roughly $1,500–$6,000 for a multi-day study; later-phase trials for people who already have the illness typically offer a smaller stipend—often $25–$100 per visit—plus travel reimbursement. Amounts are set case-by-case by the study sponsor and ethics board, based on the time you give up, the inconvenience or discomfort involved (blood draws, overnight stays, special diets), and any out-of-pocket costs, and they must be prorated so you can stop at any time and still receive payment for the visits you’ve completed.

      How much weight can you lose with ESG surgery?

      Large studies find that people lose roughly 15–20 % of their starting weight after endoscopic sleeve gastroplasty—about 30–50 lb if you begin at 200–250 lb—and most keep the bulk of that off for at least two years when they stay in a structured nutrition and activity program. Your exact result can be higher or lower depending on your initial BMI, how closely you follow the dietary and lifestyle plan, and whether you attend regular follow-up visits with the bariatric team.

      What weight is considered obese?

      For adults, obesity starts at a body-mass index (BMI) of 30 kg/m²—so take your height in metres, square it, and multiply by 30 to see the weight cut-off. Example: 5′4″ (1.63 m) → 1.63² × 30 ≈ 88 kg / 194 lb; 6′0″ (1.83 m) → 1.83² × 30 ≈ 102 kg / 225 lb. BMI is only a quick gauge—muscle mass, ethnicity, waist size, and other health factors matter too—so use it as a starting point and confirm risks with your healthcare professional.

      Who is eligible for tirzepatide?

      Tirzepatide is eligible for adults in two settings: (1) as Mounjaro to improve blood-sugar control in type-2 diabetes, and (2) as Zepbound for weight management if you have obesity (BMI ≥ 30) or are overweight (BMI ≥ 27) with at least one related condition such as high blood pressure, abnormal cholesterol, sleep apnea, heart disease, or type-2 diabetes. You are NOT a candidate if you’re pregnant, under 18, or have a personal or family history of medullary thyroid cancer or MEN-2; your doctor will also screen for issues like pancreatitis, severe stomach problems, or other risks before prescribing. In short, meeting the diabetes or weight criteria and having no major contraindications makes you a potential candidate, but final approval comes after a thorough medical review.

      What tests are done for unexplained weight gain?

      Doctors usually start with a history and physical exam, then order a small “baseline” panel—complete blood count, comprehensive metabolic panel (kidney + liver), fasting glucose/HbA1c, cholesterol, thyroid-stimulating hormone, and a pregnancy test in women of child-bearing age. If exam findings point to a specific cause, they add focused tests: e.g., cortisol or prolactin for suspected hormone tumors, sex-hormone and ultrasound for possible PCOS, heart or kidney studies for fluid retention, or imaging of the pituitary/adrenal glands. In short, everyone gets the core labs, and any further blood work or scans are chosen only when your symptoms or medications suggest a particular problem.

      Can a morbidly obese person lose weight without surgery?

      Yes. Rigorous studies show that people with class III (“morbid”) obesity can shed 6-8 % of their starting weight through weekly lifestyle-coaching programs, and often 15-20 % when the same program is paired with new once-a-week injections such as semaglutide (Wegovy) or tirzepatide (Zepbound); endoscopic sleeve procedures add another non-surgical option in the same range. Because even a 5-10 % loss markedly improves blood pressure, diabetes and sleep-apnea, doctors usually start with dietitian-guided eating plans, gradual activity and behaviour counselling, then add medication if weight hasn’t dropped by about 5 % after three months—saving surgery for those who still need more help.

      How to get rid of fat deposits on legs?

      You can’t melt fat from your legs alone, so aim for gradual overall weight loss (a modest calorie deficit built around whole foods) while doing both full-body cardio and leg-strength exercises such as squats or lunges 2-3 times a week—the combo burns calories and builds muscle that makes legs look firmer as fat comes off. If your legs stay disproportionately large, painful or bruise easily, ask a clinician about lipedema or other medical causes, because lifestyle changes help most people but specialised treatment is sometimes needed.

      How to get Ozempic for weight loss?

      Ozempic (semaglutide) can be prescribed for weight loss, but it is technically an off-label use; most clinicians instead start with the weight-loss version of the same drug, Wegovy. To pursue either one, confirm you meet typical criteria (BMI ≥30, or ≥27 with a weight-related condition), then see a primary-care doctor, endocrinologist, or an obesity-medicine/telehealth service that can review your labs, rule out contraindications, and submit any required prior-authorization to your insurer or the manufacturer’s savings program. Expect a gradual dose-escalation schedule, routine follow-ups for side-effects such as nausea, and the need to pair the medication with diet and activity changes to maintain the ~15 % average weight loss seen in clinical trials.

      Which drink is good for belly fat loss?

      No drink can “melt” belly fat on its own; losing abdominal fat still comes down to taking in fewer calories than you burn. The most studied helpers are plain water (pre-meal water can curb appetite), unsweetened green tea or black coffee (their caffeine and, for green tea, catechins give a small metabolic boost). Choose these without added sugar, pair them with balanced meals and regular exercise, and they can support—rather than drive—belly-fat loss.

      Popular Searches

      By Condition

      Depression Clinical Trials in Delaware

      Anxiety Clinical Trials in Delaware

      Schizophrenia Clinical Trials in Delaware

      ADHD Clinical Trials in Delaware

      Bipolar Disorder Clinical Trials in Delaware

      Multiple Sclerosis Clinical Trials in Delaware

      Autism Clinical Trials in Delaware

      Treatment Resistant Depression Clinical Trials in Delaware

      Borderline Personality Disorder Clinical Trials in Delaware

      Social Anxiety Disorder Clinical Trials in Delaware

      Parkinson's Disease Clinical Trials in Delaware

      Alzheimer's Disease Clinical Trials in Delaware

      By Location

      Clinical Trials near Newark, DE

      Clinical Trials near Wilmington, DE

      Clinical Trials near Lewes, DE

      Clinical Trials near Rehoboth Beach, DE

      Clinical Trials near Seaford, DE

      Clinical Trials near Millville, DE

      Clinical Trials near Frankford, DE

      Clinical Trials near Dover, DE

      Clinical Trials near Milford, DE

      Clinical Trials near Hockessin, DE

      Clinical Trials near Georgetown, DE

      Clinical Trials near Middletown, DE

      Other People Viewed

      By Subject

      26 Tinnitus Trials near Miami, FL

      Top Clinical Trials near Greenfield, IN

      161 Clinical Trials near Beaver, PA

      Top Lung Cancer Clinical Trials near San Antonio, TX

      Top Depression Clinical Trials near Manchester, NH

      Top Clinical Trials near Brentwood, TN

      Top Clinical Trials near Goodyear, AZ

      Top Lyme Disease Clinical Trials

      17 Eczema Trials near Tulsa, OK

      Top Focal Epilepsy Clinical Trials

      Top Clinical Trials near Kenner, LA

      Top Clinical Trials near Battle Creek, MI

      By Trial

      ION283 for Lafora Disease

      Visual-Acoustic Biofeedback for Speech Sound Disorder

      CagriSema for Type 2 Diabetes

      Combination Therapy for Breast Cancer

      Criteria-Based Rehabilitation for Shoulder Injuries

      Axitinib + Anti-OX40 Antibody for Kidney Cancer

      Stress Reactivity Test for Takotsubo Syndrome

      Spironolactone for Alzheimer's Disease

      Telehealth Exercise Program for Arthritis

      Epidural Steroids for Back Pain

      Health Information Technology for Sexually Transmitted Infections

      PDT for Head and Neck Cancer